Epitopea Announces License and Research Collaboration Agreement with MSD to Identify Cryptigen™ Tumor-Specific Antigens
Epitopea, a transatlantic cancer immunotherapeutics company developing accessible, off-the-shelf RNA-based immunotherapies, ...
FierceBiotech3d
Merck pens $300M-per-product collab with Epitopea to locate 'hidden' tumor antigens
Merck & Co. has penned a $300 million biobucks-per-product deal with cancer biotech Epitopea to identify previously secret ...
Pharm Exec2d
Epitopea Strikes Research Collaboration with Merck, Appoints Klaus Edvardsen as Chief Medical Officer
Under terms of the deal, Epitopea and Merck will work to identify Cryptigen tumor-specific antigens through Epitopea’s CryptoMap platform.
The Pharma Letter3d
Merck & Co sees enough in Epitopea to sign deal
Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co ...
manilatimes15d
Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer
CAMBRIDGE, United Kingdom and MONTREAL, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies, ...
MM&M1d
Rx Rundown: Moderna, Sanofi, GSK and more
Millie, a modern maternity clinic, secured $12 million in Series A funding led by existing investors RH Capital, TMV, ...
Yahoo Finance15d
Epitopea Appoints Klaus Edvardsen M.D., Ph.D. as Chief Medical Officer
CAMBRIDGE, United Kingdom and MONTREAL, Feb. 07, 2025 (GLOBE NEWSWIRE) -- Epitopea, a transatlantic cancer immunotherapeutics company developing accessible off-the-shelf RNA-based immunotherapies ...